Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants
-
Histogenics (HSGX) Prices Public Offering of Common Stock, Warrants
-
Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants
-
Histogenics (HSGX) Announces Proposed Common Share Public Offering
-
Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants
-
Histogenics (HSGX) to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data, Potential Regulatory Pathway
-
Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
-
Histogenics Corporation to Present at Canaccord Genuity’s 38th Annual Growth Conference
-
Histogenics Corporation to Present at Upcoming Investor Conferences
-
Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
-
Histogenics (HSGX) Prices 2.34M Common Shares at $2.35/Sh
-
Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock
-
Histogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth Conference
-
Histogenics Corporation to Present at Upcoming Investor Conferences
-
Histogenics Corporation to Present at the Canaccord Genuity Growth Conference
-
Histogenics Corporation to Present at Upcoming Investor Conferences
-
Histogenics Corporation to Present at the Canaccord Genuity Growth Conference
-
Histogenics Corporation to Present at the Canaccord Genuity Growth Conference
-
Histogenics Corporation to Present at the 2015 Canaccord Genuity Musculoskeletal Conference
-
Canaccord Genuity Starts Histogenics Corp. (HSGX) at Buy
-
Histogenics (HSGX) IPO Opens Higher after Weak Pricing
-
Histogenics (HSGX) IPO Prices at $11, Below Expected Range
-
Histogenics Corporation Announces Pricing of Initial Public Offering

